Imatinib as effective therapy for dermatofibrosarcoma protuberans: Proof of concept of the autocrine hypothesis for cancer

Future Oncology

Volumn 4, Issue 2, 2008, Pages 211-217

  Handolias, Despina ^a   McArthur, Grant A ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Autocrine; Dermatofibrosarcoma protuberans; Imatinib; Oncogene; PDGF receptor; Tyrosine kinase

Indexed keywords

COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; GROWTH FACTOR RECEPTOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SIGNAL PEPTIDE; VASCULOTROPIN A;

AUTOCRINE EFFECT; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; DERMATOFIBROSARCOMA PROTUBERANS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; AUTOCRINE COMMUNICATION; DERMATOFIBROSARCOMA; EPIDERMAL GROWTH FACTOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 43049086735     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.2.211     Document Type: Review

References (33)

1. Sporn MB, Roberts AB: Autocrine growth factors and cancer. Nature 313, 745-747 (1985).
2. Waterfield MD, Scrace GT, Whittle N et al.: Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 304. 35-39 (1983).
3. Fleming TF, Matsui T, Molloy CJ, Robbins KC, Aaronson SA: Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors. Proc. Natl. Acad. Sci. USA 86, 8063-8067 (1989).
4. Moody TW, Pert CB, Gazdar AF, Carney DN, Minna JD: High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science 214, 1246-1248 (1981).
5. Cuttitta F. Carney DN, Mulshine J et al.: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316, 823-826 (1985).
6. Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine. Growth Factor Rev. 15, 275-286 (2004).
7. Harsh GR, Keating MT, Escobedo JA, Williams LT: Platelet derived growth factor (PDGF) autocrine components in human tumor cell lines. J. Neurooncol. 8(1), 1-12 (1990).
8. Erlandsson A, Brannvall K, Gustafsdottir S, Westermark B, Forsberg-Nilsson K: Autocrine/paracrine platelet-derived growth factor regulates proliferation of neural progenitor cells. Cancer Res. 66, 8042-8048 (2006).
9. Vassbotn FS, Ostman A, Langeland N et al.: Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line. J. Cell. Physiol. 158, 381-389 (1994).
10. Jechlinger M, Sommer A, Moriggi R et al.: Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Invest. 116, 1561-1570 (2006).
11. Kim R. Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 103, 1800-1809 (2005).
12. Delattre O, Zucman J, Plougastel B et al.: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumors. Nature 359, 162-165 (1992).
13. Riggi N, Cironi L, Provero P et al.: Development of Ewing's sarcoma from primary bone marrow-derived mesenchyrnal progenitor cells. Cancer Res. 65, 11459-11468 (2005).
14. Benini S, Manara MC, Cerisano V et al.: Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int. J. Cancer 108, 358-366 (2004).
15. Mercurio AM, Bachelder RE, Bates RC, Chung J: Autocrine signaling in carcinoma: VEGF and the α6p4 integrin. Semin. Cancer Biol. 14, 115-122 (2004).
16. Patel PH, Chaganti RS, Motzer RJ: Targeted therapy for metastatic renal cell carcinoma. Br. J. Cancer 94, 614-619 (2006).
17. Nicol D, Hii SI, Walsh M et al.: Vascular endothelial growth factor expression is increased in renal cell carcinoma. J. Urol. 157, 1482-1486 (1997).
18. Motzer RJ, Bukowski RM: Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 24, 5601-5608 (2006).
19. Warren RS, Yuan H. Matli MR, Gillett NA, Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95, 1789-1797 (1995).
20. Ramnarain DB, Park S, Lee DY et al.: Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res. 66, 867-874 (2006).
21. Wang D, Patil S, Li W, Humphrey LE, Brattain MG, Howell GM: Activation of the TGFα autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 21, 2785-2796 (2002).
22. Haran-Ghera N, Krautghamer R, Lapidot T, Peled A, Dominguez MG. Stanley ER: Increased circulating colony-stimulating factor-1 (CSF-1) in SJL/J mice with radiation-induced acute myeloid leukemia (AML) is associated with autocrine regulation of AML cells by CSF-1. Blood 89, 2537-2545 (1997).
23. Janowska-Wieczorek A, Belch AR, Jacobs A et al.: Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies. Blood 77, 1796-1803 (1991).
24. West RB, Rubin BP, Miller MA et al.: A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc. Natl Acad. Sci. USA 103, 690-695 (2006).
25. Kauser DS, Vanetten RA: Tyrosine kinases as targets for cancer. N. Eng. J. Med. 353, 172-187 (2005).
26. Gloster HM Jr: Dermatofibrosarcoma protuberans. J. Am. Acad. Dermatol. 35, 355-374; quiz 375-356 (1996).
27. Fiore M, Miceli R, Mussi C et al.: Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J. Clin. Oncol. 23. 7669-7675 (2005).
28. Suit H, Spiro I, Mankin HJ, Efird J, Rosenberg AE: Radiation in management of patients with dermatofibrosarcoma protuberans. J. Clin. Oncol. 14, 2365-2369 (1996).
29. Sandberg AA, Bridge JA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatafibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet. Cytogenet. 140, 1-12 (2003).
30. Simon MP, Pedeutour F, Sirvent N et al.: Deregulation of the platelet-derived growth factor B-chain gene via fusion with Collagen gene COLA1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 15, 95-98.(1997).
31. Simon MP, Navarro M, Roux D, Pouyssegur J: Structural and functional analysis of a chimeric protein COL1Al-PDGFB generated by the translocation t(17;22)(q22;q13.1) in dermatofibrosarcoma protuberans (DP). Oncogene 20, 2965-2975 (2001).
32. Sjoblom T, Shimizu A, O'Brien KP et al.: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61, 5778-5783 (2001).
33. McArthur GA, Demetri GD, van Oosterom A et al.: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J. Clin. Oncol. 23, 866-873 (2005).